Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Neurotoxicity

Currently viewing:

Administrative data

Endpoint:
neurotoxicity: acute oral
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Study period:
1994
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: see 'Remark'
Remarks:
GLP - Guideline study, tested with the source substance zinc(bis) dimethyldithiocarbamate (CAS No. 137-30-4). In accordance to the ECHA guidance document “Practical guide 6: How to report read-across and categories (March 2010)”, the reliability was changed from RL1 to RL2 to reflect the fact that this study was conducted on an read-across substance

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1994
Report date:
1994

Materials and methods

Test guidelineopen allclose all
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 418 (Delayed Neurotoxicity of Organophosphorus Substances Following Acute Exposure)
Deviations:
yes
Remarks:
This study protocol is not fully in compliance with OECD guideline 418 (1995): • Rats instead of hens • 14 days observation and not 21 • No biochemical measurements • Tests were performed only once a week and not twice Histo
Deviations:
yes
Remarks:
• Histopathology was performed on solely 5 rats/sex from control group and maximal dose • No positive control
GLP compliance:
yes
Limit test:
no

Test material

Constituent 1
Reference substance name:
Ziram
EC Number:
205-288-3
EC Name:
Ziram
Cas Number:
137-30-4
IUPAC Name:
zinc bis(dimethyldithiocarbamate)
Constituent 2
Reference substance name:
zinc bis dimethyldithiocarbamate
IUPAC Name:
zinc bis dimethyldithiocarbamate
Details on test material:
Test material: Ziram
Lot/Batch number: V528/8331AA
Description: White powder
Purity: 97.8%
Stability: The stability of the test substance and test substance preparations in vehicle were confirmed by analysis.

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Charles River Breeding Laboratories, Portage, Michigan, USA
- Age at study initiation: 43 days
- Weight at study initiation: 189 - 253 g (males), 138 - 190 g (females)

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
corn oil
Analytical verification of doses or concentrations:
no
Duration of treatment / exposure:
Single oral dose
Frequency of treatment:
n.a.
Doses / concentrations
Remarks:
Doses / Concentrations:
0, 15, 300 and 600 mg/kg bw
Basis:
nominal conc.
No. of animals per sex per dose:
12 per sex for 0, 15, 300 mg/kg bw
16 per sex for 600 mg/kg bw
Control animals:
yes, concurrent vehicle
Details on study design:
Concentration in vehicle: Not reported.
Total volume applied: 7.5 ml/kg bw
Postexposure period: 14 days

Examinations

Observations and clinical examinations performed and frequency:
MORTALITY
- Twice daily.

CLINICAL SIGNS
- Daily except on days were FOB was conducted.

BODY WEIGHT
- Pre-study and on days 7 and 14.
Specific biochemical examinations:
No anticholinergic substances used
Neurobehavioural examinations performed and frequency:
FUNCTIONAL OBSERVATIONAL BATTERY (FOB) & LOCOMOTOR ACTIVITY
- Pre-study, 4 h after treatment and on days 7 and 14.


Sacrifice and (histo)pathology:
Pathology
- All animals
- All central and peripheral tissues were preserved. Brain weight and dimensions were recorded as well as all gross abnormalities or changes in coloration.

HISTOPATHOLOGY
- Yes, on five animals per sex from control and high-dosage group.
- Nerve tissues: brain, spinal cord, gasserian ganglion/trigeminal nerves, lumbar dorsal/ventral root fibers and dorsal root ganglion at T13 – L4, cervical dorsal/ventral root fibers and dorsal root ganglion at C3 – C8, eyes with optic nerves, sciatic nerves, sural nerves, tibial nerves, peroneal nerves, forelimbs, tail
Other examinations:
no
Positive control:
none

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Mortality:
mortality observed, treatment-related
Body weight and weight changes:
effects observed, treatment-related
Food consumption and compound intake (if feeding study):
effects observed, treatment-related
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Clinical biochemistry findings:
not examined
Behaviour (functional findings):
effects observed, treatment-related
Gross pathological findings:
effects observed, treatment-related
Neuropathological findings:
no effects observed
Details on results:
MORTALITY
- Four males (= 25%) and seven females (= 44%) died following dose administration with 600 mg test material. In the 300 mg/kg bw group one female (= 8%) died.

CLINICAL SIGNS
- Signs observed in the 300 and 600 mg/kg bw groups included gait alterations, abnormal respiration and excreta and a distended abdomen during the first days after exposure.
- Other treatment-related signs in the 300 and 600 mg/kg bw groups consisted of staining/material on various body surfaces during the first week.
- Additional observations on two males in the mid-dose group included cyanosis, hypothermia, enophthalmus, unkempt appearance hypoactivity and ptosis.

BODY WEIGHT
- Transient significant reductions were apparent in the 300 and 600 mg/kg bw group during week 1. For animals receiving 300 mg/kg bw this effect persisted up to termination.

FOB & LOCOMOTOR ACTIVITY
- Administration of 300 and 600 mg test material/kg bw produced alterations in posture, palpebral closure and feces consistency. Out of these only the alterations in posture persisted up to termination.
- Further on animals receiving 300 and 600 mg/kg bw showed lacrimation, salivation, changes in fur appearance, changes in respiratory rate and/or character, red deposits around mouth and crusty deposits around mouth and nose on the day of administration. Additionally at 600 mg/kg bw decreased muscle tone was noticed. The only findings observed on days 7 and 14 were limited to the already mentioned two males in the mid-dose group.
- Moreover ziram induced at a level of 300 and 600 mg/kg bw impaired mobility and altered gait at day 0, which persisted partly in two males receiving 300 mg/kg bw up to termination.
- Sensory observations revealed test article related effects at 300 and 600 mg/kg bw including absent tail pinch and olfactory responses as well as an absent or only slight startle response. In addition absent forelimb and/or hindlimb extensions in females were attributed to the treatment.
- For neuromuscular parameters no treatment-related effects were observed.
- Physiological observations showed a decrease in body temperature at 300 and 600 mg/kg bw at day 0 and 7. On day 14 the decrease was limited on the already mentioned males receiving 300 mg/kg bw.
- Finally treatment with ziram caused decreases in mean ambulatory and total motor activity counts in animals receiving 300 and 600 mg/kg bw with full recovery until day 14.

PATHOLOGY
Unscheduled sacrifice:
- White contents in the stomach and/or intestine were observed at 300 and 600 mg/kg bw as well as distention of the stomach and/or intestine. Two females of the 600 mg/kg bw group were emaciated (no abdominal adipose tissue was present).

Scheduled sacrifice:
No treatment-related effects on brain weight or dimensions were noticed.


Effect levels

open allclose all
Dose descriptor:
LOAEL
Effect level:
ca. 300 mg/kg bw/day (nominal)
Sex:
male/female
Basis for effect level:
other: = 312.6 mg KDDC (a.s.)/kg bw = 625.2 mg KDDC (50% solution as supplied)/kg bw, based on reduction of brain and body weight and body temperature, impairment of walk, tiptoe gait and mobility
Remarks on result:
other:
Dose descriptor:
NOAEL
Effect level:
ca. 15 mg/kg bw/day (nominal)
Sex:
male/female
Basis for effect level:
other: = 15.6 mg KDDC (a.s.)/kg bw = 31.2 mg KDDC (50%)/kg bw
Remarks on result:
other:

Any other information on results incl. tables

Table 7.9.1-A1         Acute neurotoxic effects

Parameter / Dose

0 mg/kg

15 mg/kg

300 mg/kg

600 mg/kg

Dose-response

+/–

Clinical signs

Yes

Yes

Yes

Yes

Body weight

Changes in FOB

Yes

Yes

Yes

Yes

Applicant's summary and conclusion